Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
AstraZeneca
Harvard Business School
McKinsey
Boehringer Ingelheim

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for BBI608

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug BBI608?

BBI608 is an investigational drug.

There have been 22 clinical trials for BBI608. The most recent clinical trial was a Phase 3 trial, which was initiated on August 1st 2014.

The most common disease conditions in clinical trials are Colorectal Neoplasms, Carcinoma, and Carcinoma, Hepatocellular. The leading clinical trial sponsors are Boston Biomedical, Inc, Sumitomo Dainippon Pharma Co., Ltd., and Australasian Gastro-Intestinal Trials Group.

There are sixteen US patents protecting this investigational drug and one hundred and eighty-eight international patents.

Recent Clinical Trials for BBI608
TitleSponsorPhase
Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal CancerAustralasian Gastro-Intestinal Trials GroupPhase 2
A Study to Evaluate the Mass Balance of 14C-Napabucasin in Healthy Adult Male SubjectsBoston Biomedical, IncPhase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Drug Interaction Potential of Napabucasin in Healthy VolunteersBoston Biomedical, IncPhase 1

See all BBI608 clinical trials

Clinical Trial Summary for BBI608

Top disease conditions for BBI608
Top clinical trial sponsors for BBI608

See all BBI608 clinical trials

US Patents for BBI608

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
BBI608   Start Trial Anticancer agent Kyoto Pharmaceutical Industries, Ltd. (Kyoto, JP) Sumitomo Dainippon Pharma Co., Ltd. (Osaka, JP)   Start Trial
BBI608   Start Trial 3-substituted carbonyl-naphtho[2,3-B]furane derivative or pharmaceutically acceptable salt thereof Boston Biomedical, Inc. (Cambridge, MA)   Start Trial
BBI608   Start Trial Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer BOSTON BIOMEDICAL, INC. (Cambridge, MA) SUMITOMO DAINIPPON PHARMA CO., LTD. (Osaka-shi, Osaka, JP)   Start Trial
BBI608   Start Trial Method for producing 2-acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione SUMITOMO DAINIPPON PHARMA CO., LTD. (Osaka, JP)   Start Trial
BBI608   Start Trial Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents The University of North Carolina at Chapel Hill (Chapel Hill, NC)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for BBI608

Drugname Country Document Number Estimated Expiration Related US Patent
BBI608 Australia 2015272560 2034-06-09   Start Trial
BBI608 Canada 2951627 2034-06-09   Start Trial
BBI608 European Patent Office 3153508 2034-06-09   Start Trial
BBI608 Japan 6549115 2034-06-09   Start Trial
BBI608 Japan WO2015190489 2034-06-09   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Dow
Baxter
McKesson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.